OMERS ADMINISTRATION Corp Grows Stock Holdings in West Pharmaceutical Services, Inc. $WST

OMERS ADMINISTRATION Corp boosted its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 23.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,769 shares of the medical instruments supplier’s stock after purchasing an additional 2,442 shares during the period. OMERS ADMINISTRATION Corp’s holdings in West Pharmaceutical Services were worth $3,200,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Elyxium Wealth LLC acquired a new position in West Pharmaceutical Services in the 4th quarter valued at $25,000. Bayban acquired a new stake in West Pharmaceutical Services during the 4th quarter worth $27,000. Private Trust Co. NA boosted its stake in West Pharmaceutical Services by 156.4% during the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 61 shares during the last quarter. DV Equities LLC purchased a new stake in shares of West Pharmaceutical Services during the fourth quarter worth $28,000. Finally, Cornerstone Planning Group LLC raised its position in shares of West Pharmaceutical Services by 90.9% in the first quarter. Cornerstone Planning Group LLC now owns 105 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 50 shares during the last quarter. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

West Pharmaceutical Services Trading Up 1.0%

Shares of West Pharmaceutical Services stock opened at $331.52 on Tuesday. The stock has a 50 day moving average of $337.57 and a 200 day moving average of $287.85. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. The firm has a market capitalization of $23.33 billion, a price-to-earnings ratio of 42.45, a PEG ratio of 2.56 and a beta of 1.16. West Pharmaceutical Services, Inc. has a fifty-two week low of $223.83 and a fifty-two week high of $386.00.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29. The company had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The company’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. As a group, research analysts predict that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th will be paid a dividend of $0.22 per share. This represents a $0.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio (DPR) is 11.27%.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on WST. Weiss Ratings restated a “hold (c)” rating on shares of West Pharmaceutical Services in a report on Friday. Stephens reiterated an “overweight” rating and set a $360.00 price objective on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. Morgan Stanley boosted their price objective on West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. Wolfe Research assumed coverage on West Pharmaceutical Services in a report on Monday, June 1st. They issued an “outperform” rating and a $375.00 target price for the company. Finally, KeyCorp lifted their price target on West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $364.42.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.